The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
复制标题
DOI：
10.1016/j.clim.2020.108450
复制
发表时间：
2020-06-01
影响因子：
8.6
通讯作者：
Ciceri, Fabio
中科院分区：
文献类型：
--
作者：
Mastaglio, Sara;Ruggeri, Annalisa;Ciceri, Fabio
急性呼吸窘迫综合征（ARDS）是COVID-19肺炎的一种毁灭性临床表现，主要基于免疫驱动的病理学。越来越多的证据表明，COVID-19是由适应不良的宿主炎症反应引发的，这种反应涉及先天免疫途径的过度激活。虽然已经记录了涉及IL-6和其他细胞因子的“细胞因子风暴”，但补体C3激活已经被认为是在SARS-CoV感染的临床前模型中加剧肺损伤的初始效应机制。C3靶向干预可能为COVID-19患者的补体介导的炎症损伤提供更广泛的治疗控制。在此，我们报告了一例因COVID-19肺炎导致严重ARDS的患者的临床病程，该患者使用基于坎普他汀的补体C3抑制剂AMY-101安全且成功地治疗。
Acute respiratory distress syndrome (ARDS) is a devastating clinical manifestation of COVID-19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence suggests that COVID-19 is fueled by a maladaptive host inflammatory response that involves excessive activation of innate immune pathways. While a "cytokine storm" involving IL-6 and other cytokines has been documented, complement C3 activation has been implicated as an initial effector mechanism that exacerbates lung injury in preclinical models of SARS-CoV infection. C3-targeted intervention may provide broader therapeutic control of complement-mediated inflammatory damage in COVID-19 patients. Herein, we report the clinical course of a patient with severe ARDS due to COVID-19 pneumonia who was safely and successfully treated with the compstatin-based complement C3 inhibitor AMY-101.